Eagle Pharmaceuticals, Inc. (25)

Browse by Contract Category

Contracts

Amendment to Development and Licensing Agreement, by and between the Company and Robert One, LLC, dated December 9, 2022 (Filed With SEC on December 14, 2022)
Amended and Restated Severance Benefit Plan, effective as of December 9, 2022 (Filed With SEC on December 9, 2022)
Security Purchase Option Agreement, by and between the Registrant, Enalare Therapeutics Inc. and the other parties thereto, dated August 8, 2022 (Filed With SEC on August 9, 2022)
Announcement, dated March 28, 2022 (Filed With SEC on March 28, 2022)
License Agreement, dated as of August 6, 2021, between the Registrant and AOP Orphan Pharmaceuticals GmbH (Filed With SEC on November 9, 2021)
Fifth Amendment to Lease Agreement between the Registrant and CAPSTONE TICE BLVD LLC. dated as of August 8, 2019 (Filed With SEC on March 2, 2020)
Settlement and License Agreement, by and between Teva Pharmaceuticals International GmbH (Filed With SEC on November 9, 2022)
Securities Purchase Agreement, by and between the Registrant and Enalare Therapeutics Inc., dated August 8, 2022 (Filed With SEC on August 9, 2022)
Guaranty Agreement to Loan Agreement, by and among the Registrant, Acacia Pharma Limited and Cosmo Technologies Ltd., dated June 9, 2022 (Filed With SEC on August 9, 2022)
Form of Shareholder Lock-up Agreement (Filed With SEC on March 28, 2022)
Lock-up Agreement, dated March 27, 2022, by and between Eagle Pharmaceuticals, Inc. and Cosmo Pharmaceuticals N.V (Filed With SEC on March 28, 2022)
Form of Director Undertaking (Filed With SEC on March 28, 2022)
Form of Shareholder Undertaking (Filed With SEC on March 28, 2022)
Co-operation Agreement, dated March 27, 2022, by and between Eagle Pharmaceuticals, Inc. and Acacia Pharma Group plc (Filed With SEC on March 28, 2022)
License Agreement, dated as of August 19, 2021, between the Registrant and Combioxin SA (Filed With SEC on November 9, 2021)
Form of Performance Stock Unit Grant Package (2014 Equity Incentive Plan) (Filed With SEC on March 5, 2021)
Form of Performance Stock Unit Grant Package (2014 Equity Incentive Plan) (Filed With SEC on March 5, 2021)
Consulting Agreement between (Filed With SEC on November 2, 2020)
Co-Promotion Agreement, dated January 7, 2020, between the Registrant and Tyme Technologies Inc (Filed With SEC on May 11, 2020)
Co-Promotion Agreement with Tyme Technologies, Inc., dated January 7, 2020 (Filed With SEC on March 2, 2020)
Settlement Agreement, by and between the Registrant and Eli Lilly and Company, dated December 13, 2019 (Filed With SEC on March 2, 2020)
Description of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 2, 2020)
Securities Purchase Agreement, dated January 7, 2020, between the Company and Tyme (Filed With SEC on January 8, 2020)
Eagle Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan (Filed With SEC on December 16, 2019)
Fourth Amendment to the Exclusive License Agreement, dated April 12, 2019, by and between Eagle Pharmaceuticals, Inc., a Delaware corporation and Teva Pharmaceuticals... (Filed With SEC on May 7, 2019)